http://www.mynewsdesk.com/se/pressroom/sanofi-aventis Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Wed, 19 Jun 2013 10:30:50 +0200 Sanofi (EURONEXT: SAN and NYSE: SNY) and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, announce today the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/curie-cancer-and-sanofi-cooperate-in-research-on-ovarian-cancer-878186?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/curie-cancer-and-sanofi-cooperate-in-research-on-ovarian-cancer-878186?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Tue, 18 Jun 2013 15:05:01 +0200 Sanofi announced today that clinical data highlighting the company’s ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA. In total, more than 60 abstracts representing new data sets on Sanofi diabetes drugs, investigational drugs or medical devices are part of the official scientific program. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-to-present-new-clinical-data-including-results-from-the-investigational-new-insulin-u300-at-the-american-diabetes-association-73rd-877890?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-to-present-new-clinical-data-including-results-from-the-investigational-new-insulin-u300-at-the-american-diabetes-association-73rd-877890?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Mon, 10 Jun 2013 10:23:37 +0200 Sanofi (EURONEXT: SAN and NYSE: SNY) announced today thatthe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency(EMA) has issued a positive opinion for inclusion in the Lantus® (insulin glargine) product label of safety and efficacy data from the insulin glargine cardiovascular (CV) outcomes trial ORIGIN(Outcome Reduction with Initial Glargine INtervention). http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/origin-results-on-lantus-r-cardiovascular-safety-integrated-into-european-union-product-label-874651?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/origin-results-on-lantus-r-cardiovascular-safety-integrated-into-european-union-product-label-874651?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Fri, 24 May 2013 15:25:55 +0200 Paris, France - May 23, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) is pleased to announce today the appointment of David Loew, as Senior Vice President, Commercial Operations, Europe, effective July 1st , 2013. He will report to Peter Guenter in his new role as Executive Vice President, David will join the Global Leadership Team and become Chairman of the European Strategic Committee. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-appoints-david-loew-senior-vice-president-commercial-operations-europe-869983?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-appoints-david-loew-senior-vice-president-commercial-operations-europe-869983?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Mon, 06 May 2013 11:41:47 +0200 Pollensäsongen blir längre och längre samtidigt som antalet pollenallergiker växer stadigt. Bara i Sverige lider uppskattningsvis 1 150 000 personer av pollenallergi. Trots detta finns det idag ett stort kunskapsglapp kring pollenallergi. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sol-vaerme-vaar-pollensaesong-862721?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sol-vaerme-vaar-pollensaesong-862721?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Thu, 25 Apr 2013 11:41:48 +0200 Sanofi and its subsidiary Genzyme announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome can prevent or delay conversion to clinically definite multiple sclerosis (CDMS). http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/once-daily-aubagio-r-delayed-onset-of-clinically-definite-multiple-sclerosis-ms-in-topic-study-859763?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/once-daily-aubagio-r-delayed-onset-of-clinically-definite-multiple-sclerosis-ms-in-topic-study-859763?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Fri, 12 Apr 2013 09:36:16 +0200 Paris, France, and South San Francisco, California - April 11, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and PATH’s Drug Development program, established through an affiliation with OneWorld Health, today announced the launch of the large-scale production line of semisynthetic artemisinin at Sanofi’s Garessio site in Italy. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-path-announce-the-launch-of-large-scale-production-of-semisynthetic-artemisinin-against-malaria-855131?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-path-announce-the-launch-of-large-scale-production-of-semisynthetic-artemisinin-against-malaria-855131?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Tue, 05 Feb 2013 09:21:00 +0100 Sanofi meddelar idag att de erhållit ett europeiskt godkännande av aflibercept 25 mg/ml för behandling av metastaserad kolorektal cancer. Aflibercept, som i Sverige kommer att marknadsföras under namnet ZALTRAP, ges som andra linjens behandling i kombination med FOLFIRI. Kombinationen har i studier visat signifikant förlängd total överlevnad hos patienter med metastaserad kolorektalcancer. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-faar-europeiskt-godkaennande-foer-zaltrap-aflibercept-foer-behandling-av-metastaserad-kolorektal-cancer-834136?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-faar-europeiskt-godkaennande-foer-zaltrap-aflibercept-foer-behandling-av-metastaserad-kolorektal-cancer-834136?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Mon, 04 Feb 2013 08:46:00 +0100 Sanofi lanserar ny behandling: den första prandiella GLP-1 receptoragonisten, som tas en gång per dag i samband med måltid http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/lyxumia-r-lixisenatid-faar-europeiskt-godkaennande-foer-behandling-av-typ-2-diabetes-833685?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/lyxumia-r-lixisenatid-faar-europeiskt-godkaennande-foer-behandling-av-typ-2-diabetes-833685?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Tue, 18 Dec 2012 10:00:00 +0100 Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Hanspeter Spek, President, Global Operations, will retire from his current role in mid-2013. A succession plan will be announced in due course. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-president-global-operations-to-retire-823624?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-president-global-operations-to-retire-823624?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Mon, 03 Dec 2012 10:24:00 +0100 Sanofi announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-compounds-to-be-featured-in-178-abstracts-at-american-society-of-hematology-annual-meeting-818449?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-compounds-to-be-featured-in-178-abstracts-at-american-society-of-hematology-annual-meeting-818449?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Wed, 28 Nov 2012 13:46:35 +0100 Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-ranks-third-on-the-access-to-medicine-foundation-s-2012-atm-index-817224?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-ranks-third-on-the-access-to-medicine-foundation-s-2012-atm-index-817224?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Mon, 19 Nov 2012 14:12:53 +0100 Sanofi meddelade idag att kommittén för humanläkemedel (CHMP) vid Europeiska läkemedelsmyndigheten (EMA) har utfärdat ett positivt yttrande där man rekommenderar godkännande av Lyxumia ® (lixisenatid) en gång dagligen för behandling av vuxna med typ 2-diabetes för att uppnå glykemisk kontroll i kombination med orala glukossänkande läkemedel och/eller basinsulin. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-faar-positivt-utlaatande-fraan-chmp-foer-lyxumia-r-lixisenatid-foer-behandling-av-vuxna-med-typ-2-diabetes-814212?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-faar-positivt-utlaatande-fraan-chmp-foer-lyxumia-r-lixisenatid-foer-behandling-av-vuxna-med-typ-2-diabetes-814212?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Thu, 15 Nov 2012 15:45:48 +0100 Sanofi and T1D Exchange, a non-profit organization focused on type 1 diabetes, announced today on World Diabetes Day that they will collaborate on the TEENs registry study. The aim of the study is to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-t1d-exchange-to-launch-worldwide-study-to-investigate-factors-for-optimal-care-for-young-people-with-diabetes-813313?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-t1d-exchange-to-launch-worldwide-study-to-investigate-factors-for-optimal-care-for-young-people-with-diabetes-813313?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Fri, 09 Nov 2012 08:30:00 +0100 Hjärt- och Lungsjukas Riksförbund har tillsammans med Sanofi producerat Flimmerrapporten som presenteras idag. Omkring 210 000 svenskar beräknas lida av förmaksflimmer. Risken att få sjukdomen ökar med åldern och var fjärde person över 40 år förväntas drabbas av förmaksflimmer någon gång i livet. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/att-leva-med-foermaksflimmer-811168?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/att-leva-med-foermaksflimmer-811168?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Thu, 01 Nov 2012 15:44:57 +0100 Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012, online issue of The Lancet. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/genzyme-announces-publication-of-lemtrada-alemtuzumab-pivotal-studies-in-the-lancet-809090?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/genzyme-announces-publication-of-lemtrada-alemtuzumab-pivotal-studies-in-the-lancet-809090?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Thu, 01 Nov 2012 10:13:13 +0100 Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-regeneron-announce-publication-of-phase-2-results-with-ldl-cholesterol-lowering-pcsk9-antibody-in-the-new-england-journal-of-medicine-808852?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-regeneron-announce-publication-of-phase-2-results-with-ldl-cholesterol-lowering-pcsk9-antibody-in-the-new-england-journal-of-medicine-808852?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Fri, 12 Oct 2012 16:41:58 +0200 Sanofi and its subsidiary Genzyme announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/genzyme-presents-second-phase-iii-study-of-once-daily-oral-aubagio-r-teriflunomide-confirming-significant-impact-on-disability-802922?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/genzyme-presents-second-phase-iii-study-of-once-daily-oral-aubagio-r-teriflunomide-confirming-significant-impact-on-disability-802922?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Tue, 09 Oct 2012 15:37:20 +0200 Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADA TM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/genzyme-to-present-new-data-from-aubagio-r-and-lemtradatm-clinical-development-programs-at-ectrims-801591?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/genzyme-to-present-new-data-from-aubagio-r-and-lemtradatm-clinical-development-programs-at-ectrims-801591?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis Mon, 08 Oct 2012 17:25:05 +0200 Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO). http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/journal-of-clinical-oncology-publishes-phase-iii-results-of-zaltrap-r-aflibercept-velour-study-in-previously-treated-metastatic-colorectal-cancer-801255?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/journal-of-clinical-oncology-publishes-phase-iii-results-of-zaltrap-r-aflibercept-velour-study-in-previously-treated-metastatic-colorectal-cancer-801255?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news sanofi-aventis